Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Mizuho Securities USA LLC

Mizuho Securities USA LLC increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 42.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 18,868 shares of the medical equipment provider’s stock after purchasing an additional 5,662 shares during the period. Mizuho Securities USA LLC’s holdings in Zimmer Biomet were worth $1,993,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet during the fourth quarter worth approximately $25,000. Dunhill Financial LLC boosted its stake in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the period. Brooklyn Investment Group purchased a new position in Zimmer Biomet during the 3rd quarter worth $35,000. Kentucky Trust Co acquired a new position in Zimmer Biomet in the fourth quarter valued at $39,000. Finally, OFI Invest Asset Management purchased a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $40,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.95% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ZBH. Raymond James decreased their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, JMP Securities reissued a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $111.31 on Tuesday. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90. The stock has a market cap of $22.16 billion, a P/E ratio of 25.01, a PEG ratio of 1.95 and a beta of 1.04. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average of $106.86 and a two-hundred day moving average of $106.86.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm posted $2.20 EPS. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.86%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.